Guggenheim Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $450
Guggenheim Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $450
古根海姆維持對Vertex Pharmicals的買入,將目標股價上調至450美元
Guggenheim analyst Debjit Chattopadhyay maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $445 to $450.
古根海姆分析師黛布吉特·查託帕迪亞維持Vertex Pharmicals(納斯達克股票代碼:VRTX)的買入並將目標股價從445美元上調至450美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。